Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells

Poly-(ADP)-ribose polymerase inhibitors (PARPi) and platinum-based drugs are promising therapies for triple negative breast cancers (TNBC) with BRCA1 or BRCA2 loss. PARPi(s) show better efficacies when combined with platinum-based therapy, however, acquisition of PARPi resistance has been linked wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gajan, Ambikai, Sarma, Ashapurna, Kim, Seongho, Gurdziel, Katherine, Wu, Gen Sheng, Shekhar, Malathy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339968/
https://www.ncbi.nlm.nih.gov/pubmed/34367977
http://dx.doi.org/10.3389/fonc.2021.694793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339968/
https://www.ncbi.nlm.nih.gov/pubmed/34367977
http://dx.doi.org/10.3389/fonc.2021.694793

Ejemplares similares